Animal Cell Patents (Class 435/7.21)
  • Patent number: 11401544
    Abstract: Methods and kits for preparing re-usable single cells are described. Cell components are anchored using a nano-scale scaffold to create a re-usable single cell. The nano-scale scaffold may be a polyacrylamide nano-scale scaffold. Methods to determine modifications of the genome, transcriptome, or epigenome are described.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: August 2, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Giovanna Tosato, Hidetaka Ohnuki
  • Patent number: 11384126
    Abstract: The present invention relates to compositions and methods for inhibiting DHHC3 palmitoyltransferase for treating cancer. Described herein, are methods of inhibiting expression or activity of programmed death-ligand 1 (PD-L1) in a cell of a subject, e.g., a human subject, in need thereof are carried out by administering to the subject an effective amount of a palmitoyltransferase inhibitor, thereby inhibiting the expression or activity of PD-L1 in the subject. The palmitoyltransferase comprises an Asp-His-His-Cys motif (DHHC)-type protein. Exemplary DHHC-type proteins include DHHC3, DHHC5, DHHC7, and DHHC17.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: July 12, 2022
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Chandan Sharma, Martin E. Hemler
  • Patent number: 11352443
    Abstract: The present invention provides a chimeric protein comprising: a) a single chain variable fragment (scFv) that binds to a mammalian IgE at an epitope within the amino acid sequence VDGQKATNIFPYTAPGTK (SEQ ID NO:1) of canine IgE or at an epitope within the corresponding amino acid sequence of a different mammalian species; b) a linker peptide; and c) an amino acid sequence comprising an IgE high affinity receptor alpha chain, and methods of use thereof.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: June 7, 2022
    Assignee: North Carolina State University
    Inventors: Bruce Hammerberg, Sitka Eguiluz-Hernandez, Thierry Olivry
  • Patent number: 11346841
    Abstract: Disclosed is a specimen measurement system including: a specimen measuring device that measures a specimen; a determination unit that determines whether or not the specimen is to be measured by a flow cytometer, based on a measurement result of the specimen measuring device.
    Type: Grant
    Filed: September 24, 2019
    Date of Patent: May 31, 2022
    Assignee: SYSMEX CORPORATION
    Inventors: Takaaki Nagai, Hideki Hirayama, Hiroo Tatsutani, Tomohiro Tsuji
  • Patent number: 11332518
    Abstract: The present specification discloses SNAP-25 compositions, methods of making ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, methods of detecting BoNT/A activity, and methods of detecting neutralizing ?-BoNT/A antibodies.
    Type: Grant
    Filed: July 15, 2021
    Date of Patent: May 17, 2022
    Assignee: Allergan, Inc.
    Inventors: Ester Fernandez-Salas, Joanne Wang, Patton E. Garay, Lina Wong, D. Dianne Hodges, Kei Roger Aoki
  • Patent number: 11286274
    Abstract: The disclosure provides derivatives of both the oxidized form and the reduced form of nicotinamide riboside (NR) and nicotinic acid riboside (NAR). The NR and NAR derivatives have improved stability and bioavailability compared to NR and NAR, and can increase cellular NAD+ levels and improve mitochondrial function. Therefore, the NR and NAR derivatives are useful for treating mitochondrial diseases, mitochondria-related diseases and conditions, and other disorders and conditions.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: March 29, 2022
    Assignee: MitoPower LLC
    Inventors: Gangadhara Ganapati, Atignal Shankara Rao Arvind
  • Patent number: 11254744
    Abstract: Antigen binding constructs that bind to desired targets are disclosed, for example antibodies, including antibody fragments (such as scFv and minibodies) that bind to a target molecule, and have one or more of the disclosed hinges are described herein. Methods of use are described herein.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: February 22, 2022
    Assignee: IMAGINAB, INC.
    Inventors: Chio Mui Chan, Jean Gudas, Tove Olafsen, Daulet Kadyl Satpayev, Michael Yuri Torgov
  • Patent number: 11247581
    Abstract: A battery control device capable of obtaining an allowable charge/discharge current value can further accurately reflect a polarization state of a battery. A battery controller includes a first allowable current value calculation unit, a battery equivalent circuit model, and a correction amount calculation unit. Assuming a non-polarization state, a current limit value of the battery based on an open circuit voltage and upper and lower limit voltages set in the battery, the first allowable current value calculation unit calculates a first allowable current value Imax1. The battery equivalent circuit model estimates a polarization state of the battery when the current limit value is being calculated. The correction unit calculates an allowable current value correction value based on the estimated polarization state for correcting Imax1. A second allowable current value Imax2 which is the corrected first allowable current value is output as an allowable charge/discharge current value of the battery.
    Type: Grant
    Filed: May 18, 2020
    Date of Patent: February 15, 2022
    Assignee: VEHICLE ENERGY JAPAN, INC.
    Inventors: Kei Sakabe, Keiichiro Ohkawa, Takanori Yamazoe, Ryohhei Nakao, Masahiro Yonemoto
  • Patent number: 11203785
    Abstract: The present invention relates to a method for assessing, evaluating and/monitoring the purity of a mesenchymal stem cells preparation, in particular of an adipose stem cells preparation, comprising measuring the expression level of at least one growth factor.
    Type: Grant
    Filed: May 9, 2016
    Date of Patent: December 21, 2021
    Assignees: UNIVERSITÉ CATHOLIQUE DE LOUVAIN, CLINIQUES UNIVERSITAIRES SAINT-LUC, NOVADIP BIOSCIENCES SA
    Inventor: Denis Dufrane
  • Patent number: 11203639
    Abstract: Antigen binding constructs that bind to desired targets are disclosed, for example antibodies, including antibody fragments (such as scFv and minibodies) that bind to a target molecule, and have one or more of the disclosed hinges are described herein. Methods of use are described herein.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: December 21, 2021
    Assignee: IMAGINAB, INC.
    Inventors: Chio Mui Chan, Jean Gudas, Tove Olafsen, Daulet Kadyl Satpayev, Michael Yuri Torgov
  • Patent number: 11193927
    Abstract: Methods, devices, and systems for automated cellular analysis of a body fluid sample are disclosed. The methods, devices, and systems apply watershed transform to data, generated by flowing a body fluid sample through a flow cytometer, to determine threshold(s) to be used for analysis of the data.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: December 7, 2021
    Assignee: Abbott Laboratories
    Inventors: Wenjing Li, Emily H. Lin, Jiong Wu
  • Patent number: 11186611
    Abstract: A peptide and a peptide complex of the present invention exhibit an anti-obesity effect by inhibiting fat accumulation and decomposing already accumulated fat, and exhibit an excellent effect with respect to diabetes by effectively reducing blood sugar. The peptide and the peptide complex of the present invention decrease the expression of PPAR?, ACC, and aP2, which are adipogenic markers, increase the expression of pHSL, AMPK-?1, CGI-58, and ATGL, which are lipolytic factors, and reduce the size of fat cells and blood cholesterol values. The peptide and the peptide complex of the present invention, which have excellent activity and safety, can be advantageously applied to drugs and quasi-drugs.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: November 30, 2021
    Assignee: CAREGEN CO., LTD.
    Inventors: Yong Ji Chung, Eun Mi Kim
  • Patent number: 11181482
    Abstract: A mobile phone-based system for ELISA (MELISA). The MELISA system can perform all steps of ELISA procedure and output hormone concentration values. The system includes a heater that keeps the temperature required for sample incubation, illumination system for sample image capturing, and a digital camera system. All components are enclosed in a dark box to create optimal light conditions for image capturing. After sample images are captured, they are digitally processed, and hormone concentration values are reported based on colorimetric data from the samples. The system can be used to complete all steps of the assay, including incubation and reading. It is lightweight, can be fabricated at low cost, is portable, and can transfer test results via mobile phone. MELISA can be calibrated for accurate measurements of progesterone and has demonstrated successful measurements with the calibrated system.
    Type: Grant
    Filed: September 5, 2018
    Date of Patent: November 23, 2021
    Assignee: University of South Florida
    Inventors: Anna Pyayt, Arsenii Zhdanov, Jordan Keefe, Luis Franco-Waite
  • Patent number: 11161898
    Abstract: The present invention relates, in part, to isolated antibodies that specifically interact with and show measurable binding affinity to an epitope of the amyloid-beta (A?) protein. Such antibodies may be used for the modulation of A? activity and/or aggregation or amyloidosis, to study the effects of the A? protein on cell function and, in certain embodiments, for the treatment and/or prevention of a disease or condition associated with A? activity, aggregation, and/or amyloidosis.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: November 2, 2021
    Assignee: rPeptide LLC
    Inventors: Quentin Florence, Nanda Menon, William Moffitt, Bill Lunsford, III
  • Patent number: 11147829
    Abstract: This current invention provides methods and agents for preventing and treating autoimmune and lymphoproliferative disease by targeting pathogenic age-associated B cells as well as methods of detecting these pathogenic age-associated B cells as a method of diagnosing and predicting autoimmune disease and other lymphoproliferative and chronic inflammatory disorders. The current invention also provides targets for drug development and basic research for autoimmune diseases and other lymphoproliferative and chronic inflammatory disorders.
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: October 19, 2021
    Assignee: NEW YORK SOCIETY FOR THE RUPTURED AND CRIPPLED MAINTAINING THE HOSPITAL FOR SPECIAL SURGERY
    Inventors: Alessandra Pernis, Michela Manni
  • Patent number: 11116867
    Abstract: Embolic materials, suspensions, kits and related methods useful for embolization are disclosed. An embolic material can comprise a resorbable microsphere including cross-linked gelatin as its primary ingredient and having a substantially spherical shape with a diameter of about 50 micrometers to about 1,500 micrometers, inclusive. The microsphere can optionally include one or both of a marker or an active agent. The microsphere can be cross-linked, such as with glutaraldehyde or formaldehyde, which can affect the microsphere's in vivo degradation profile and ability to withstand a sterilization process at certain temperatures. In an embodiment, the microspheres can resorb during an in vivo time period of between about 24 hours and about 15 weeks, inclusive. An embolization suspension can include a plurality of resorbable microspheres and a liquid carrier, and the suspension can be disposed in a syringe, vial or other applicator for administration to a patient.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: September 14, 2021
    Assignee: TELEFLEX LIFE SCIENCES LIMITED
    Inventors: Stephen Penegor, Jason Isenburg, James Murto
  • Patent number: 11109801
    Abstract: A method of measuring efficacy of test treatment of an autoimmune disease in an animal in a vivarium is described. Animal activity data is collected at multiple times during the night. Sequential time regions of the night are identified as high-activity, activity-drop, or low-activity regions. Embodiments are described to quantify a drop, during the night, of an animal's activity level. These quantified activity-drop scalars for consecutive nights are accumulated in an animal health dataset. This dataset is compared to healthy animals, a standard of care or a reference treatment for the first disease to determine efficacy of the test treatment. One embodiment quantifies an activity-drop by fitting straight-line curves through the data in the three nightly regions. Other embodiment uses a Fourier transform on a circle, LASSO, RANSAC or regression analyses for curve fitting. Another embodiment compares areas under data curves in the regions. Animals may be housed in cages with other animals.
    Type: Grant
    Filed: September 21, 2019
    Date of Patent: September 7, 2021
    Assignee: Recursion Pharmaceuticals, Inc.
    Inventors: Laura Schaevitz, Daniel J. Ford
  • Patent number: 11114204
    Abstract: A computer-based system to determine whether patients should be treated as inpatients or outpatients. The invention makes personalized predictions about the risk and timing of adverse outcomes for the patient, and further assesses how this risk and timing may vary if the patients are treated as inpatients or outpatients. This information informs how patients are assigned to an appropriate therapy. The invention includes logic relevant to predicting patient risk, decoupling patient risk into components inherent to the patient as well as additions/subtractions associated with the choice of treatment, and predicting the timing of adverse outcomes given censored data. The invention can be extended to use in a broad range of other application domains (e.g., matching learners to courses either offered in-classroom or online for education).
    Type: Grant
    Filed: April 3, 2015
    Date of Patent: September 7, 2021
    Assignee: Predictive Modeling, Inc.
    Inventors: John V. Guttag, Zeeshan H. Syed
  • Patent number: 11099185
    Abstract: The invention is directed to the use of biomarkers to determine responsiveness of an individual with wet AMD to treatment with a VEGF antagonist, to diagnose and distinguish dry and wet AMD and to determine the risk of conversion of a dry AMD disease to a wet AMD disease.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: August 24, 2021
    Assignee: maintect GmbH
    Inventors: Franz Grus, Christina Korb, Norbert Pfeiffer
  • Patent number: 11092599
    Abstract: The invention relates to biosensors for detecting odorants, especially a biosensor that mimics odorant detection by a mammal, for example, humans, dogs or cats. The field of the invention also related to the standardization of odors for scent, smell and taste using the biosensor of the invention, and the discovery of agonists, antagonists, and mixtures of odorants for creating new odors, masking odors, enhancing odors, and designing odors.
    Type: Grant
    Filed: February 23, 2017
    Date of Patent: August 17, 2021
    Assignee: Aromyx Corporation
    Inventors: Chris Hanson, William Harries, Victor Todd Cushman, Ed Costello
  • Patent number: 11083751
    Abstract: The present application relates to tumor-associated dendritic cell (TADC) preparations and their use in treatment of tumor metastasis.
    Type: Grant
    Filed: February 22, 2017
    Date of Patent: August 10, 2021
    Assignees: VIB VZW, Vrije Universiteit Brussel, Universiteit Gent
    Inventors: Jo Van Ginderachter, Damya Laoui, Jiri Keirsse, Martin Guilliams
  • Patent number: 11029318
    Abstract: In some embodiments, the present invention provides methods for treating pregnant patients at risk of adverse pregnancy outcome, including, in some embodiments, by measuring one or more of a level of iC3b, intact C3, and total C3.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: June 8, 2021
    Assignee: Kypha, Inc.
    Inventors: Nicholas Staten, Alfred Kim, Paul Olson
  • Patent number: 11022606
    Abstract: A cell information acquisition method may include: binding a binding substance to a receptor on a cell membrane surface of a cell, the binding substance being bindable to the receptor; permeabilizing a cell membrane of the cell after the binding; labeling a receptor in an intracellular area of the cell with a binding substance labeled with a first labeling substance after the permeabilizing; causing a specimen including the cell to flow through a flow path after the labeling; irradiating the cell included in the specimen flowing through the flow path with light; and acquiring a signal based on light generated from the first labeling substance in the cell irradiated with light.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: June 1, 2021
    Assignee: SYSMEX CORPORATION
    Inventors: Keiko Yoshikawa, Yuma Oka, Shingo Fujiyama
  • Patent number: 10983114
    Abstract: An improved method for the preparation of tetrameric antibody complexes directly on the surface of target entities in a sample is described. In particular, this method involves linking, in the sample, a first target entity with a second target entity in a sample using antibodies with specificity for the first and second target entities.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: April 20, 2021
    Assignee: STEMCELL Technologies Inc.
    Inventor: Andy Isamu Kokaji
  • Patent number: 10962555
    Abstract: The present invention provides for the first time the identification of fetal neural exosomal biomarkers isolated from maternal plasma useful in diagnosing fetal neurodevelopmental outcomes. The invention also provides the identification of neonatal neural exosomal biomarkers isolated from neonatal plasma useful in diagnosing neonatal neurodevelopmental outcomes The present invention therefore provides methods, kits and systems for diagnosing fetal neurodevelopmental outcomes, by examining relevant proteins and RNA in fetal neural exosomes isolated from a maternal plasma and neonatal neural exosomes isolated from neonatal plasma.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: March 30, 2021
    Assignee: TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Laura Goetzl, Edward Goetzl
  • Patent number: 10953045
    Abstract: Immune-potentiating compositions include cells exhibiting enhanced antigen-presenting functions. The compositions are generally useful in facilitating the stimulation of host immune cell responses, including selective and targeted immune cell responses, and are particularly useful in the treatment and/or prophylaxis of cancers, tumors and pathogenic infections.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: March 23, 2021
    Assignee: CANCURE LIMITED
    Inventor: Stephen Ralph
  • Patent number: 10940187
    Abstract: Disclosed in this application are compositions which include digestive enzymes and which are formulated to reduce one or more symptoms of Schizophrenia or a Schizophreniform Disorder. Also disclosed is a method for treating an individual with Schizophrenia or a Schizophreniform Disorder using digestive enzymes and their derivatives to alleviate the symptoms of Schizophrenia or a Schizophreniform Disorder. The method comprises administering to the individual an effective amount of digestive enzymes that are either naturally or recombinantly derived, or their derivatives, in an amount effective to reduce one or more symptoms of Schizophrenia or a Schizophreniform Disorder.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: March 9, 2021
    Assignee: CUREMARK, LLC
    Inventors: Joan M. Fallon, Matthew Heil, James Szigethy, James Fallon
  • Patent number: 10930373
    Abstract: A system for analyzing biological data, comprising: a storage configured to store a plurality of data files containing biological data obtained from a plurality of devices; a server configured to: host a plurality of applications, each configured to be implemented on the server and to provide analysis, manipulation, comparison, visualization, or a combination thereof, of the biological data included in the data files, wherein the plurality of applications allow a user to analyze different data files related to the same sample and compare the results of the analysis.
    Type: Grant
    Filed: March 24, 2015
    Date of Patent: February 23, 2021
    Assignee: Life Technologies Corporation
    Inventors: Nivedita Sumi Majumdar, Harrison Leong, Shakila Pothini, David Hoard, Christopher Fong, Pratik Simon Soares, Salil Kumar, Thomas Wessel, Manjula Aliminati, Levente Egry
  • Patent number: 10920193
    Abstract: Described herein are chemically defined, adherent culture protocols for generating functional motor neurons characteristic of diverse hindbrain and spinal cord regions, with high efficiency.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: February 16, 2021
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Ethan Scott Lippmann, Neha Sehgal, Randolph Scott Ashton
  • Patent number: 10914746
    Abstract: The invention relates to the field of the diagnosis and prognosis methods of molecular pathologies. In particular, the invention relates to methods for determining the diagnosis of an ectatic disease of the cornea in a subject, for determining the risk of developing an ectatic disease of the cornea in a subject, for determining the clinical outcome of a subject suffering from an ectatic disease of the cornea and for selecting a subject to be treated with a therapy for an ectatic disease of the cornea based on the determination of the expression levels of TLR2 and/or TLR4 markers. The invention also relates to the use of the TLR2 and/or TLR4 as diagnosis and prognosis markers for an ectatic disease of the cornea.
    Type: Grant
    Filed: February 16, 2016
    Date of Patent: February 9, 2021
    Assignees: UNIVERSIDADE DE SANTIAGO DE COMPOSTELA, SERVIZO GALEGO DE SAUDE (SERGAS)
    Inventors: María Isabel Lema Gesto, José Antonio Castillo Sánchez, Tomás Sobrino Moreiras, Francisco Campos Perez
  • Patent number: 10810904
    Abstract: Described herein are kits and methods for identifying the likelihood of having a food sensitivity or intolerance, and determining dietary modifications accordingly. For example, the likelihood of having sensitivities, intolerances or allergies to gluten, lactose, FODMAPs and others tested and calculated. Additionally, diet modifications can be determined according to the likelihood of particular sensitivities, and the effectiveness of diet modifications can be evaluated by monitoring of meals and subsequent symptoms, and evaluating the monitoring information. Through application of the methods herein, dietary intake and symptom data may be collected and aggregated to evaluate the effect or desirability of particular foods on a population of interest.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: October 20, 2020
    Assignees: CEDARS-SINAI MEDICAL CENTER, THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Brennan Spiegel, William D. Chey
  • Patent number: 10751384
    Abstract: The present invention provides a pharmaceutical formulation comprising a therapeutically effective amount of a polypeptide corresponding to one or more of SEQ ID No(s) 1, 2, 3 or 4. The therapeutically effective amount of polypeptide may be formulated for administration to a subject in need of treatment as an oral formulation, a parenteral formulation, a topical formulation, an aqueous formulation, a solid formulation, a lyophilized formulation, or a trans-dermal formulation. Also disclosed are methods for treating at least one of diabetes, hyperglycemia, hypercholesterolemia, and hypertension in a subject, comprising administering to the subject a therapeutically effective amount of a polypeptide according to SEQ ID Nos. 1-4.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: August 25, 2020
    Assignee: IMAGINE PHARMA LLC
    Inventors: Ngoc Thai, Jonathan Pollett
  • Patent number: 10712339
    Abstract: A microfluidic device for more accurately modeling the in vitro environment in which cancer occurs is disclosed. The microfluidic device includes a surface defining one or more microfluidic channels, a first three dimensional scaffold comprising one or more cancer cells that is spatially separated from the one or more microfluidic channels, a second three dimensional scaffold, at least a portion of which is contacting and in fluid communication with the first three dimensional scaffold, and that is spatially separated from the one or more microfluidic channels, and a third three dimensional scaffold, at least a portion of which is contacting and in fluid communication with the one or more microfluidic channels and the second three dimensional scaffold. The device can be used to assay anti-cancer agents, or as a system for modeling the growth, behavior, or metastasis and tumor formation of cancer cells.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: July 14, 2020
    Assignee: Arizona Board of Regents on behalf of Arizona State University
    Inventors: Mehdi Nikkhah, Danh Truong
  • Patent number: 10668147
    Abstract: Complexes suitable for targeting and killing a human target cell comprising a first polypeptide with a binding structure for binding the complex to the cellular surface receptor CD89 (e.g. with an anti CD89 antibody) presented on the cell surface of the human target cell and a second polypeptide comprising a toxic effector domain, preferably Pseudomonas exotoxin A); to nucleic acid molecules encoding said complexes, vectors, host cells containing the nucleic acids and methods for preparation and producing such complexes; compositions and methods for using said complexes for the treatment of diseases, in particular of cancer diseases like leukemia.
    Type: Grant
    Filed: March 25, 2015
    Date of Patent: June 2, 2020
    Assignees: FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V., RHEINISCH-WESTFAELISCHE TECHNISCHE HOCHSCHULE AACHEN
    Inventors: Christoph Stein, Radoslav Mladenov, Bernhard Stockmeyer, Stefan Barth, Lea Christin Schenke, Rainer Fischer
  • Patent number: 10669314
    Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for interleukin-6, and provides an IL-6 binding polypeptide comprising the sequence EEX3X4AWX7EIH X11 LPNLX16X17X18QX20 X21AFIX25X26LX28X29. The present disclosure also relates to the use of such an IL-6 binding polypeptide as a therapeutic, prognostic and/or diagnostic agent.
    Type: Grant
    Filed: June 15, 2015
    Date of Patent: June 2, 2020
    Assignee: AFFIBODY AB
    Inventors: Fredrik Frejd, Elin Gunneriusson, Ingmarie Höidén-Guthenberg, Per-Ake Nygren, Susanne Klint, Feifan Yu
  • Patent number: 10588941
    Abstract: The invention provides compositions and methods for targeting CCR10 and/or the CCR10/ligand axis to modulate the immune response in a subject.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: March 17, 2020
    Assignee: THE PENN STATE RESEARCH FOUNDATION
    Inventors: Na Xiong, Mingcan Xia
  • Patent number: 10564158
    Abstract: Methods and systems are provided for characterizing responses of a ligand-functionalized surface, which rely on dispensing a segmented liquid flow including liquid sequences, each including: an analyte segment including biomolecules of analyte; a spacer segment; and a wash segment including a washing liquid, whereby spacer segments separate wash segments from analyte segments in the dispensed segmented liquid flow. A measurement cycle is performed for each of the liquid sequences of the segmented liquid flow being dispensed. A measurement cycle includes: ejecting an analyte segment of each liquid sequence toward the ligand-functionalized surface and extracting, from each liquid sequence, a spacer segment succeeding the analyte segment as the latter is being ejected; ejecting a wash segment succeeding the extracted spacer segment in each liquid sequence to flush unbound and/or weakly bound biomolecules of analytes from the surface; and reading out a signal of bound biomolecules of analytes on the surface.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: February 18, 2020
    Assignee: International Business Machines Corporation
    Inventors: Moran Bercovici, Govind V. Kaigala, Xander F. van Kooten, Nadya Ostromohov, Federico Paratore
  • Patent number: 10564150
    Abstract: This disclosure relates generally to the field of immunological-based diagnostic assays including an assay to measure cell-mediated immunoresponsiveness. The present disclosure teaches diagnosis of a subject's exposure to an antigen based on cell-mediated immunoresponsiveness with enhanced sensitivity which is achieved by adding a non-reducing sugar during incubation of the sample with the antigen.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: February 18, 2020
    Assignee: Cellestis Limited
    Inventors: Jeff Boyle, Ashley Knights, Carmen Munian
  • Patent number: 10556015
    Abstract: The invention provides compositions and methods for effective lysosomal targeting mediated by PCSK9. In particular, the compositions and methods provided by the invention may be used to treat lysosomal storage diseases such as Pompe Disease and Sanfilippo Syndrome Type B, and they may be used for targeting lysosomal enzymes to the various muscles of the human body.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: February 11, 2020
    Assignee: Criteo S.A.
    Inventors: Bohong Zhang, Michael F. Concino
  • Patent number: 10551392
    Abstract: The present invention, relates to the use of TFF3 in the diagnosis and detection of Barrett's Oesophagus using non-invasive, non-endoscopic methods.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: February 4, 2020
    Assignee: Covidien LP
    Inventors: Pierre Lao-Sirieix, Rebecca C. Fitzgerald
  • Patent number: 10548941
    Abstract: The present invention provides a composition comprising a therapeutically effective amount of a polypeptide, peptide, or analog corresponding to one or more of SEQ ID NO(s) 1, 2, 3 or 4, and or more of a pharmaceutically acceptable carrier, pharmaceutically acceptable diluent, and/or pharmaceutically acceptable excipient. The polypeptide therapeutic of the present invention may be formulated for administration to a subject in need of treatment as an oral formulation, a parenteral formulation, a topical formulation, an aqueous formulation, a solid formulation, a lyophilized formulation, or a trans-dermal formulation. Also disclosed is a method for treating at least one of diabetes, and/or hyperglycemia, and/or hypercholesterolemia, and/or hypertension in a subject, comprising: administering to the subject a polypeptide of the invention or formulation of the invention.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: February 4, 2020
    Assignee: IMAGINE PHARMA
    Inventors: Ngoc Thai, Jonathan Pollett
  • Patent number: 10545156
    Abstract: The invention relates to biomarkers associated with preterm delivery. More specifically, the invention provides methods of measuring biomarkers including but not limited to cytokines, cytokine receptors, cytokine receptor antagonists, chemokines, chemokine receptors, and/or chemokine receptor antagonists found in women that are at risk for preterm delivery. The diagnostic methods may be performed on whole blood.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: January 28, 2020
    Assignee: RPI Consulting, LLC
    Inventors: Ozlem Equils, Charles F. Simmons
  • Patent number: 10545081
    Abstract: The present invention relates to a method for the optical measurement of at least the stability and the aggregation of particles in a liquid sample which is located in a sample container, wherein the method comprises the following steps: irradiating the sample with light of at least one first wavelength in order to fluorescently excite the particles, irradiating the sample with light of at least one second wavelength in order to examine the scattering of the particles, measuring the fluorescence light which is emitted by the sample; and measuring the extinction light at the second wavelength, wherein the irradiated light of the second wavelength runs through the sample container, is reflected back, runs again through the sample container in the opposite direction and exits as extinction light, wherein the stability is determined based on the measured fluorescence light and the aggregation is measured based on the measured extinction light. The invention further relates to a corresponding apparatus.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: January 28, 2020
    Assignee: NANOTEMPER TECHNOLOGIES GMBH
    Inventors: Philipp Baaske, Stefan Duhr, Dennis Breitsprecher, Jonathan Derix
  • Patent number: 10526637
    Abstract: Methods for improving the specificity of assays for botulinum neurotoxins are described. Reporting constructs are provided that include cleavable linker sequence with genetically modified recognition and/or cleavage sites. These linker sequences act as a substrate for a botulinum neurotoxin, with cleavage of the reporting construct providing a detectable signal. When first and second neurotoxins have activity with the same substrate protein, mutation and/or deletion of a recognition and/or cleavage site associated with the second neurotoxin improves the specificity of the detectable signal for the first neurotoxin.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: January 7, 2020
    Assignee: BIOMADISON, INC.
    Inventors: Robert D. Fish, Min Dong
  • Patent number: 10473671
    Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect Chitinase-3-like protein 1 as diagnostic and prognostic biomarker assays in renal injuries.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: November 12, 2019
    Assignee: Astute Medical, Inc.
    Inventors: Joseph Anderberg, Jeff Gray, Paul McPherson, Kevin Nakamura, James Patrick Kampf
  • Patent number: 10458902
    Abstract: Disclosed is an analysis component and associated systems and methods. The analysis component can be used with an electronic device equipped with a detector for detecting light. The component comprises: a sample holder for holding the sample; a detector site at which a detector, or a detector portion of the electronic device, is to be positioned to detect light reflecting off the sample; and a structural component spacing the sample holder from the detector site by a predetermined distance; wherein the lysis component is configured to allow light from a light source to illuminate the sample such that light reflected by the sample can be received by the detector for analyzing the sample. An associated system comprises the analysis component and a detector for detecting light reflected off the sample.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: October 29, 2019
    Assignee: Australian Sensing and Indentification Systems Pty. Ltd.
    Inventors: Sandra Ast, John Canning
  • Patent number: 10450607
    Abstract: The present disclosure provides compositions, methods, systems, and devices for polynucleotide processing. Such polynucleotide processing may be useful for a variety of applications, including polynucleotide sequencing.
    Type: Grant
    Filed: March 6, 2019
    Date of Patent: October 22, 2019
    Assignee: 10X GENOMICS, INC.
    Inventors: Benjamin Hindson, Christopher Hindson, Michael Schnall-Levin, Kevin Ness, Mirna Jarosz, Serge Saxonov
  • Patent number: 10420503
    Abstract: A method of measuring efficacy of treatment of multiple sclerosis (MS) in an animal in a vivarium is described. Animal activity data is collected at multiple times during the night. Sequential time regions of the night are identified as high-activity, activity-drop, or low-activity regions. Embodiments are described to quantify a drop, during the night, of an animal's activity level. These quantified activity-drop scalars for consecutive nights are accumulated in an animal health dataset. This dataset is compared to healthy animals or a standard of care to determine efficacy. One embodiment quantifies an activity-drop by fitting straight-line curves through the data in the three nightly regions. Another embodiment uses a Fourier transform on a circle and a linear combination. Another embodiment compares areas under data curves in the regions. Animals may be housed in cages with other animals.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: September 24, 2019
    Assignee: Vium, Inc.
    Inventors: Daniel J. Ford, Laura Schaevitz
  • Patent number: 10418126
    Abstract: Herein is reported a method for selecting or deselecting an antibody comprising a) determining for each Asp and Asn residue in an antibody Fv region the conformational flexibility of the C?-atom using a homology model ensemble, b) determining for each Asp and Asn residue in an antibody Fv region the size of the amino acid residue C-terminal to the Asp or Asn residue, and c) selecting an antibody in which the C?-atom is conformationally inflexible and/or the Asp or Asn has a big C-terminal amino acid residue, or deselecting an antibody in which the C?-atom has a moderate to high conformational flexibility and/or the Asp or Asn has a small C-terminal amino acid residue.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: September 17, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Hubert Kettenberger, Stefan Klostermann, Florian Lipsmeier, Apollon Papadimitriou, Jasmin Sydow-Andersen
  • Patent number: 10398710
    Abstract: The present invention is directed to a method for screening a regulator of mitochondrial fission using a cell treated to a protopanaxadiol (PPD)-type ginsenoside compound, a composition therefor, and a kit comprising the composition. As the use of the method for screening the regulator of mitochondrial fission of the present invention enables effective discovery of a formulation capable of preventing, improving, or treating a mitochondria-related disease, the method will be widely used for the development of a therapeutic agent for the mitochondria-related disease.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: September 3, 2019
    Assignee: INTELLIGENT SYNTHETIC BIOLOGY CENTER
    Inventors: Chul Hee Choi, Eun Soo Kim, Kyung Sun Choi, Seung Wook Ryu, Jin Gang Hou